AstraZeneca’s (AZN) new drug application for baxdrostat has been accepted for priority review by the FDA in the U.S. for the treatment of adult patients with hard-to-control hypertension as an add-on to other antihypertensive medicines when these do not provide adequate lowering of blood pressure. The Prescription Drug User Fee Act date is anticipated during the second quarter of 2026 following use of a Priority Review voucher.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca announces NDA for baxdrostat accepted for Priority Review by FDA
- Vaccine committee considers changes to childhood schedule, NY Times reports
- Midday Fly By: Nvidia invests in Synopsys, U.S. strikes pharma deal with UK
- Trump Trade: U.S. confirms agreement with U.K. on pharmaceutical pricing
- Is AstraZeneca’s Stock (AZN) a Good Investment Right Now?